Skip to content
Camptosar, Onivyde pegylated liposomal (previously known as onivyde)(irinotecan)
Camptosar, Onivyde (irinotecan) is a small molecule pharmaceutical. Irinotecan was first approved as Camptosar on 1996-06-14. It is used to treat breast neoplasms, colonic neoplasms, leukemia, lymphoma, and neoplasm metastasis amongst others in the USA. It has been approved in Europe to treat pancreatic neoplasms. The pharmaceutical is active against DNA topoisomerase 1.
Download report
Favorite
Requested
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Camptosar, Onivyde (generic drugs available since 2008-02-27)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Irinotecan hydrochloride
Tradename
Company
Number
Date
Products
ONIVYDEIpsenN-207793 RX2015-10-22
1 products, RLD, RS
CAMPTOSARPfizerN-020571 RX1996-06-14
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
camptosarNew Drug Application2020-06-01
irinotecan hydrochlorideANDA2022-04-29
onivydeNew Drug Application2020-12-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
breast neoplasmsEFO_0003869D001943C50
colonic neoplasms—D003110C18
leukemia—D007938C95
lymphoma—D008223C85.9
neoplasm metastasisEFO_0009708D009362—
non-small-cell lung carcinoma—D002289—
pancreatic neoplasmsEFO_0003860D010190C25
rectal neoplasms—D012004—
stomach neoplasmsEFO_0003897D013274C16
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Irinotecan Hydrochloride, Onivyde, Ipsen Inc
104563602036-10-15DP
109939142036-10-15DP
93394972033-06-12U-1848
93644732033-06-12U-1856
94521622033-06-12U-1899
94924422033-06-12U-1848, U-1899, U-1917
97177242033-06-12U-1848, U-2091
109807952033-06-12U-1848
113695972033-06-12U-1848
81478672028-08-29DS, DP
83292132027-01-06DS, DP
87031812025-05-02U-1434
89929702025-05-02DS, DP
97243032025-05-02DS, DP
97308912025-05-02U-1848
97823492025-05-02DS, DP
107225082025-05-02DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CE: Topoisomerase 1 (top1) inhibitors
— L01CE02: Irinotecan
HCPCS
Code
Description
J9205
Injection, irinotecan liposome, 1 mg
J9206
Injection, irinotecan, 20 mg
Clinical
Clinical Trials
1129 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151797824865515372
Stomach neoplasmsD013274EFO_0003897C162462152399
AdenocarcinomaD000230152941243
Rectal neoplasmsD012004142441240
Small cell lung carcinomaD05575292471135
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80122438——153
Pancreatic neoplasmsD010190EFO_0003860C25536612—3112
Esophageal neoplasmsD004938C159356—251
Colonic neoplasmsD003110C1816206—238
Lung neoplasmsD008175C34.9012252——38
NeuroblastomaD009447EFO_000062117201——33
Breast neoplasmsD001943EFO_0003869C509201—129
GlioblastomaD005909EFO_000051514181——27
SarcomaD01250911133—124
RhabdomyosarcomaD01220810122—120
Show 29 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Central nervous system neoplasmsD0165431514———24
Non-small-cell lung carcinomaD0022891016———21
Biliary tract neoplasmsD001661C24.9316——117
Ovarian neoplasmsD010051EFO_0003893C5668———13
GliomaD005910EFO_000052059———12
Gallbladder neoplasmsD005706EFO_0004606C2364——110
Triple negative breast neoplasmsD06472664———10
AstrocytomaD001254EFO_000027155———9
Fallopian tube neoplasmsD00518536———8
MedulloblastomaD00852727———8
Show 55 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD0085454————4
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.03————3
Hodgkin diseaseD006689C813————3
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A3————3
Anus neoplasmsD001005EFO_0003835C213————3
Appendiceal neoplasmsD001063EFO_0003880C18.13————3
Peritoneal neoplasmsD0105342————2
Burkitt lymphomaD002051C83.72————2
GanglioneuromaD0057291————1
GangliogliomaD0183031————1
Show 26 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ChemoradiotherapyD059248————11
Male breast neoplasmsD018567————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIRINOTECAN
INNirinotecan
Description
Irinotecan is a member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. It has a role as an apoptosis inducer, an EC 5.99.1.2 (DNA topoisomerase) inhibitor, an antineoplastic agent and a prodrug. It is a pyranoindolizinoquinoline, a N-acylpiperidine, a carbamate ester, a tertiary alcohol, a tertiary amino compound, a delta-lactone and a ring assembly. It is functionally related to a SN-38. It is a conjugate base of an irinotecan(1+).
Classification
Small molecule
Drug classantineoplastics (camptothecin derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
Identifiers
PDB—
CAS-ID97682-44-5
RxCUI51499
ChEMBL IDCHEMBL481
ChEBI ID80630
PubChem CID60838
DrugBankDB00762
UNII ID7673326042 (ChemIDplus, GSRS)
Target
Agency Approved
TOP1
TOP1
Organism
Homo sapiens
Gene name
TOP1
Gene synonyms
NCBI Gene ID
7150
Protein name
DNA topoisomerase 1
Protein synonyms
DNA topoisomerase I, Scl-70 antigen, topoisomerase (DNA) I, type I DNA topoisomerase
Uniprot ID
Q9UJN0
Mouse ortholog
Top1 (21969)
DNA topoisomerase 1 (Q04750)
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000810732UGT1A6, 862-9898G>Adrug response2021-03-242A
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 40,625 documents
View more details
Safety
Black-box Warning
Black-box warning for: Camptosar, Irinotecan hydrochloride, Onivyde
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
91 adverse events reported
View more details